PTC Therapeutics Inc (PTCT) reports robust first-quarter revenue and outlines strategic plans amidst regulatory challenges ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in ...

PTC Therapeutics reported a phase 2 win for its Novartis-partne | PTC Therapeutics reported a phase 2 win for its ...

WARREN, N.J. (AP) — WARREN, N.J. (AP) — PTC Therapeutics Inc. (PTCT) on Tuesday reported first-quarter earnings of $866.6 million. On a per-share basis, the Warren, New Jersey-based company said it ...

Q1 2025 Management View CEO Matthew Klein reported $190 million in revenue for Q1 2025, driven by strong contributions from the DMD franchise and royalty revenues. The company maintains over $2 ...

The phase 2 PIVOT-HD trial of Novartis-partnered PTC518 (votoplam) showed that the oral mRNA splicing modifier was able to ...

The Motley Fool. DATE Tuesday, May 6, 2025 at 4:30 p.m. ET Read More: Earn up to $845 cash back this year just by changing ...

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less ...

PTC Therapeutics Inc. advanced stock charts by Barron's. View BH3 historical stock data and compare to other stocks, and exchanges.

The biotech’s Huntingtin-targeting molecule lowered blood levels of the protein and elicited functional improvements in ...

PTC Therapeutics, Inc.’s PTCT share price has dipped by 21.98%, which has investors questioning if this is right time to buy.

Depressive symptoms rose progressively in the 15 years leading up to dementia diagnosis, with the highest elevations ...